Welcome to Bristol-Myers Squibb New Zealand
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol-Myers Squibb New Zealand aims to delivers on its commitments: to our patients and customers, to our employees, to our communities, and to our environment.
Visit our global website to find out more about Bristol-Myers Squibb worldwide.
9 June 2016: Opdivo (nivolumab) fully funded in New Zealand from 1 July 2016 for the treatment of advanced melanoma.
2 May 2016: Immuno-oncology agent Opdivo (nivolumab) approved in New Zealand for advanced melanoma and lung cancer.